Knockdown of prostaglandin reductase 1 (PTGR1) suppresses prostate cancer cell proliferation by inducing cell cycle arrest and apoptosis.

Chemoresistance is a serious problem for the treatment of androgen-independent prostate cancer (PC). The underlying molecular mechanisms by which androgen-independent PC cells acquire the capacity to proliferate remain largely unclear. The aim of this study was to investigate the biological role of prostaglandin reductase 1 (PTGR1) in prostate cancer. Data from the Oncomine database showed that PTGR1 is commonly upregulated in PC tissue in comparison to corresponding normal controls. Two PTGR1-specific short hairpin RNA (shRNA) sequences were used to block the expression of PTGR1 via a lentivirus-mediated system in the androgen-independent PC cell lines DU145 and PC 3. Functional analysis revealed that knockdown of PTGR1 significantly inhibited proliferation and colony formation by PC cells. The inhibition of cell proliferation was related to arrest of the cell cycle in the G0/G1 phase and increased apoptosis in response to PTGR1 knockdown as indicated by flow cytometry. PTGR1 silencing was found to mechanically enhance the expression of p21, caspase 3, and cleaved PARP and to decrease the level of cyclin D1. In conclusion, PTGR1 plays an essential role in PC cells and may be a potential therapeutic target for PC.

[1]  Zongyou Chen,et al.  Effect of prostaglandin reductase 1 (PTGR1) on gastric carcinoma using lentivirus-mediated system. , 2015, International journal of clinical and experimental pathology.

[2]  A. Rosenkrantz,et al.  Imaging and evaluation of patients with high-risk prostate cancer , 2015, Nature Reviews Urology.

[3]  Hossein Mahjub,et al.  Competing Risks Data Analysis with High-dimensional Covariates: An Application in Bladder Cancer , 2015, Genom. Proteom. Bioinform..

[4]  Shufeng Zhou,et al.  The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells , 2015, Drug design, development and therapy.

[5]  J. Meléndez-Zajgla,et al.  Increased expression of prostaglandin reductase 1 in hepatocellular carcinomas from clinical cases and experimental tumors in rats. , 2014, The international journal of biochemistry & cell biology.

[6]  M. Malumbres,et al.  Cyclin-dependent kinases , 2014, Genome Biology.

[7]  N. A. Stewart,et al.  Modulation of Nitro-fatty Acid Signaling , 2013, The Journal of Biological Chemistry.

[8]  Jianwen Wang,et al.  MiR‐365b‐3p, down‐regulated in retinoblastoma, regulates cell cycle progression and apoptosis of human retinoblastoma cells by targeting PAX6 , 2013, FEBS letters.

[9]  J. Niederhuber,et al.  Up-Regulation of Human Prostaglandin Reductase 1 Improves the Efficacy of Hydroxymethylacylfulvene, an Antitumor Chemotherapeutic Agent , 2012, Journal of Pharmacology and Experimental Therapeutics.

[10]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[11]  S. Fan,et al.  Gene Expression Profiling of Liver Cancer Stem Cells by RNA-Sequencing , 2012, PloS one.

[12]  B. Sarcevic,et al.  Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates. , 2010, Bioscience reports.

[13]  F. Guillemin,et al.  Assessment of Apoptosis by Immunohistochemistry to Active Caspase-3, Active Caspase-7, or Cleaved PARP in Monolayer Cells and Spheroid and Subcutaneous Xenografts of Human Carcinoma , 2009, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[14]  C. Peng,et al.  Unique Formosan Mushroom Antrodia camphorata Differentially Inhibits Androgen-Responsive LNCaP and -Independent PC-3 Prostate Cancer Cells , 2007, Nutrition and cancer.

[15]  T. Kensler,et al.  Depurinating acylfulvene-DNA adducts: characterizing cellular chemical reactions of a selective antitumor agent. , 2007, Journal of the American Chemical Society.

[16]  T. Dawson,et al.  Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death , 2006, Proceedings of the National Academy of Sciences.

[17]  Masayuki Yamamoto,et al.  Nrf2-mediated Induction of Cytoprotective Enzymes by 15-Deoxy-Δ12,14-Prostaglandin J2 Is Attenuated by Alkenal/one Oxidoreductase* , 2006, Journal of Biological Chemistry.

[18]  T. Kensler,et al.  Investigating the role of stereochemistry in the activity of anticancer acylfulvenes: synthesis, reductase-mediated bioactivation, and cellular toxicity. , 2006, Journal of medicinal chemistry.

[19]  I. Tannock,et al.  Management of advanced prostate cancer after first-line chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Fan,et al.  Caspase family proteases and apoptosis. , 2005, Acta biochimica et biophysica Sinica.

[21]  A. Gartel,et al.  Lost in transcription: p21 repression, mechanisms, and consequences. , 2005, Cancer research.

[22]  J. Denault,et al.  Apoptosis in Biochemistry and Structural Biology. 3-8 February 2004, Keystone, CO, USA. , 2004, IDrugs : the investigational drugs journal.

[23]  S. Muller,et al.  Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. , 2002, Current pharmaceutical biotechnology.

[24]  M. Kwak,et al.  Antioxidative Function and Substrate Specificity of NAD(P)H- dependent Alkenal/one Oxidoreductase , 2001, The Journal of Biological Chemistry.

[25]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.

[26]  J. V. van Brussel,et al.  Multidrug Resistance in Prostate Cancer , 1997, Oncology Research and Treatment.

[27]  T. Yano,et al.  Annatto Tocotrienol Induces a Cytotoxic Effect on Human Prostate Cancer PC3 Cells via the Simultaneous Inhibition of Src and Stat3. , 2015, Journal of nutritional science and vitaminology.